IRIDEX (IRIX) - 2023 Q1 - Earnings Call Transcript

As we look at the remainder of 2023, we expect to improve the growth rate of our glaucoma business and increase utilization. We are reiterating our guidance and continue to expect to sell 65,000 to 67,000 probes, representing growth of 9% to 12% compared to 2022. And expect to grow the G6 installed base by 225 to 250 systems. Fuad Ahmad Operating expenses for the first quarter were $8.3 million, flat compared to the same period last year. Our net loss in the quarter of -- first quarter of 2023 was $2.1 mill ...